Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fluvoxamine as an antiobsessional agent.

W K Goodman, L H Price, S A Rasmussen

    Psychopharmacology Bulletin
    |January 1, 1989
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome.

    Translational psychiatry·2017
    Same author

    The MCP-4/MCP-1 ratio in plasma is a candidate circadian biomarker for chronic post-traumatic stress disorder.

    Translational psychiatry·2017
    Same author

    Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.

    Psychological medicine·2015
    Same author

    Serotonin versus catecholamine deficiency: behavioral and neural effects of experimental depletion in remitted depression.

    Translational psychiatry·2015
    Same author

    Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder.

    Translational psychiatry·2015
    Same author

    Developing cognitive-emotional training exercises as interventions for mood and anxiety disorders.

    European psychiatry : the journal of the Association of European Psychiatrists·2014

    Fluvoxamine, a selective serotonin reuptake inhibitor, effectively treats Obsessive-Compulsive Disorder (OCD). Treatment effectiveness is not affected by depression levels, though further research is needed on its superiority over other serotonin reuptake blockers.

    Area of Science:

    • Pharmacology
    • Psychiatry
    • Neuroscience

    Background:

    • Obsessive-Compulsive Disorder (OCD) is a debilitating mental health condition.
    • Selective serotonin reuptake inhibitors (SSRIs) are a common treatment class for OCD.
    • The precise mechanisms underlying SSRI efficacy in OCD are still under investigation.

    Purpose of the Study:

    • To review existing studies on the efficacy of fluvoxamine for OCD treatment.
    • To determine if fluvoxamine's effectiveness is influenced by baseline depression severity.
    • To compare fluvoxamine's efficacy against other serotonin reuptake inhibitors.

    Main Methods:

    • Systematic review of published studies on fluvoxamine in OCD.
    • Analysis of patient data to assess the correlation between depression levels and fluvoxamine response.

    Related Experiment Videos

  • Comparison of fluvoxamine efficacy with other serotonin reuptake blockers (ongoing studies).

    • Main Results:

    • Fluvoxamine demonstrates potent and selective serotonin reuptake inhibition.
    • The antiobsessional effects of fluvoxamine are independent of baseline depression.
    • Clinical response to potent serotonin reuptake blockers can be incomplete or absent in a significant portion of patients.

    Conclusions:

    • Fluvoxamine is an effective treatment for Obsessive-Compulsive Disorder.
    • The role of monoamine reuptake blockade in OCD pathogenesis requires further elucidation.
    • Ongoing research aims to clarify fluvoxamine's comparative effectiveness in OCD treatment.